Transmission modelling to determine the benefit of using tafenoquine instead of primaquine in Brazil
Mathematical modelling of the public health impact of introducing tafenoquine alongside testing for G6PD deficiency into case management of P. vivax malaria in Brazil.
The aims of this modelling were to:
- assess the benefit of using tafenoquine instead of primaquine, assuming various levels of primaquine adherence;
- estimate the number of people receiving tafenoquine, the dependence on G6PD testing requirements (e.g. > 70% G6PD activity) and the availability of G6PD testing at various health facility levels;
- estimate the public health benefit of preventing future relapses by treating an infected individual;
- estimate the additional benefits of reducing population-level transmission by expanding access to treatment in a community.
Results:
This study was published in PLoS Medicine on 23rd April 2021. View paper here.
The below video presentation published by the American Society for Tropical Medicine and Hygiene in 2020 also outlines some of the key findings.